CorMedix adds to Neutrolin FT-stoked up move

• Thinly-traded nano cap CorMedix (CRMD +16.3%) heads north again on 60% higher volume, albeit on turnover of only 255K. Shares have doubled since the January 14 breakout in response to the FDA granting Fast Track status to Neutrolin. Adding fuel to the move was the designation of Qualified Infectious Disease Product (QIDP) status to Neutrolin on January 29.
• Previously: CorMedix up on QIDP designation (Jan. 29)
• Previously: Neutrolin Fast Track'd (Jan. 15)